The Dotinurad Tablets Market size was estimated at USD 179.34 million in 2025 and expected to reach USD 197.74 million in 2026, at a CAGR of 9.81% to reach USD 345.29 million by 2032.

Dotinurad is an oral urate-lowering medicine developed for hyperuricaemia and gout. It acts as a selective urate reabsorption inhibitor by reducing renal urate reuptake, thereby increasing urinary uric acid excretion. Its clinical relevance is tied to long-term serum urate control rather than rapid relief of acute inflammation. Treatment decisions require assessment of gout history, renal function, cardiovascular risk, concomitant medicines, and local prescribing rules. Product availability, approved indications, dosage instructions, and safety information differ by jurisdiction and should be verified through applicable regulatory sources and prescribing information.

Gout management is increasingly organized around sustained serum urate reduction, regular laboratory monitoring, and individualized dose adjustment. This approach places greater emphasis on adherence, patient education, renal assessment, and prevention of flares rather than episodic treatment alone. Selective urate reabsorption inhibition also highlights the importance of evaluating urinary uric acid handling, kidney-stone history, hydration, and interactions with medicines that affect renal function. The treatment landscape is therefore becoming more structured, evidence-led, and dependent on coordinated primary care, specialist care, and pharmacy support.

Artificial intelligence can support this therapeutic area through risk stratification, identification of patients with persistently elevated serum urate, adherence-support tools, and analysis of longitudinal laboratory and prescription data. Natural-language systems may help summarize clinical records and identify potential drug interactions, while predictive models can flag patients who may need closer follow-up. These applications require clinically validated datasets, transparent performance measures, privacy safeguards, and human oversight. AI should assist-not replace-diagnostic assessment, prescribing decisions, renal monitoring, and evaluation of adverse events.

In North America, emphasis is likely to remain on guideline-aligned treat-to-target care, insurance access, and management of comorbid kidney and cardiovascular disease. Europe is shaped by national reimbursement systems, harmonized regulatory standards, and established rheumatology guidance. Asia-Pacific combines substantial gout burden in several populations with uneven access to specialist care and laboratory monitoring. Latin America faces differences in affordability, diagnosis, and continuity of treatment between urban and rural settings. Middle East markets must account for chronic-disease clustering, prescribing practices, and health-system variation, while Africa requires attention to diagnostic capacity, medicine availability, and practical follow-up pathways. Across all regions, local labeling and pharmacovigilance requirements are decisive.

ASEAN markets present diverse regulatory, reimbursement, and diagnostic environments, making country-level implementation essential. BRICS members combine large and varied patient populations with differences in domestic manufacturing, procurement, and specialist access. The European Union benefits from shared regulatory architecture while retaining national reimbursement and prescribing decisions. G7 health systems generally have stronger laboratory infrastructure but continue to face affordability, multimorbidity, and adherence challenges. GCC countries often have well-developed specialist services alongside high chronic-disease burdens, whereas NATO members span highly diverse healthcare systems and should not be treated as a single access environment. These groupings are most useful for comparing policy coordination, not for assuming uniform clinical practice.

Australia and Canada require attention to national formularies, reimbursement criteria, and rural access. Brazil and Mexico face variation in public and private care pathways, affordability, and continuity of monitoring. China and India combine large patient populations with substantial regional differences in diagnosis, specialist availability, and medicine access. France, Germany, Italy, and Spain operate within European regulatory principles but differ in reimbursement, prescribing culture, and care coordination. Japan and South Korea have mature clinical systems with distinct national approval and reimbursement frameworks. Russia requires careful review of local availability, regulation, and supply conditions. The United Kingdom emphasizes guideline-based management, primary-care follow-up, and national health-system commissioning. In the United States, coverage policy, specialist referral, and medication-access requirements can strongly influence treatment continuity.

Industry leaders should first align product information, patient selection, dosing, contraindication checks, and monitoring procedures with each jurisdiction’s approved labeling. They should support clinicians with practical tools for serum urate follow-up, renal assessment, interaction review, and flare-management education. Patient programs should explain that urate lowering is preventive and typically requires persistence even when symptoms improve. Evidence generation should prioritize real-world adherence, renal and cardiovascular safety, use in relevant comorbidity groups, and outcomes across underrepresented populations. Digital and AI initiatives should use validated endpoints, secure data governance, explainable workflows, and clinician review. Access strategies should address reimbursement evidence, responsible supply planning, and partnerships that strengthen diagnosis and follow-up rather than encouraging inappropriate use.

This executive summary uses a structured secondary-research framework focused on the pharmacology and clinical role of dotinurad tablets. Relevant evidence should be verified against official product information, national regulatory decisions, peer-reviewed clinical studies, treatment guidelines, pharmacovigilance communications, and public health data on gout and hyperuricaemia. Regional, group, and country observations are framed as health-system and policy considerations rather than quantified commercial claims. No market estimates, market shares, forecasts, or company-specific assessments are included. Because approvals and reimbursement can change, users should confirm current information with the responsible national authority before making clinical, procurement, or investment decisions.

Dotinurad tablets occupy a clinically relevant role in urate-lowering therapy where selective inhibition of renal urate reabsorption is appropriate under approved local guidance. Their practical value depends on correct patient selection, sustained adherence, serum urate monitoring, renal and interaction assessment, and coordinated management of gout and comorbidities. Differences across regions, country systems, and patient groups make localized implementation essential. Leaders who combine regulatory discipline, clinician education, patient support, credible evidence generation, and carefully governed digital tools will be better positioned to promote safe and effective use.